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Abstract 
Background: Ergothioneine is a naturally occurring metabolite of histidine found in many foods and in high 
amounts in mushrooms. In vivo, ergothioneine acts as an antioxidant and is widely distributed in most mammalian 
tissues. While ergothioneine is sold as a dietary supplement for its antioxidant and anti-inflammatory properties, to 
date there are no published intervention trials examining its health benefits in humans. The aim of this work was to 
develop a study protocol for a pilot interventional trial that will establish the primary and secondary outcomes, and 
the power required, for a definitive randomised controlled trial to test the hypothesis that ergothioneine supplemen-
tation is beneficial for people with metabolic syndrome.
Methods: We have designed the ErgMS study as a single-centre, randomised, double-blind, placebo-controlled, 
3-arm parallel, pilot intervention trial, which aims to supplement participants with either placebo, 5 or 30 mg/day 
ergothioneine for 12 weeks. Measurements of metabolic syndrome risk factors, serum markers of oxidative stress (lipid 
peroxidation), inflammation, blood platelet function and liver function will take place at baseline, and after 6 weeks 
and 12 weeks of supplementation. In addition, we will examine if there are any changes in the serum metabolome 
in response to ergothioneine supplementation. Linear regression and two-way ANOVA will be utilised to analyse the 
association between ergothioneine and measured variables.
Discussion: The ErgMS study will be the first study to address the question does ergothioneine supplementation 
have health benefits for people with metabolic syndrome. Study results will provide preliminary data as to which dose 
may improve inflammatory markers in adults with metabolic syndrome and will inform dose and primary outcome 
selection for a definitive randomised controlled trial.
Trial registration: ISRCTN, ISRCT N2589 0011 Registered February  10th, 2021
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Introduction
Background and rationale
Ergothioneine is a naturally occurring metabolite of his-
tidine found in many different foods [1, 2]. Synthesized 
by bacteria and fungi, ergothioneine is found in particu-
larly high amounts in mushrooms. An amino acid betaine 
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(2-mercapto-histidine trimethylbetaine), ergothioneine 
has robust cytoprotective properties with roles as a metal 
chelator as well as an antioxidant, scavenging hydroxyls 
and other free radicals [3]. As recently reviewed in detail, 
a growing body of evidence implicates ergothioneine as 
an important nutrient for healthy ageing and the pre-
vention of a variety of inflammatory diseases, including 
cardiometabolic diseases [4, 5]. Notably, a long-term pro-
spective cohort study (n = 3236 participants with median 
follow-up of 21.4 years) found that higher plasma levels 
of ergothioneine were associated with significantly lower 
risk of coronary disease, cardiovascular mortality and 
overall mortality (hazard ratios per 1 SD increment of 
ergothioneine 0.85, 0.79 and 0.86 respectively), as well as 
a more ‘health-conscious food pattern’ [6].
In vivo, ergothioneine is transported across cell 
membranes by the solute carrier family 22 member’s 4 
and 15 (SLC22A4, SLC22A15) [7–10]. Although many 
SLC22 family members are non-selective transport-
ers, evidence suggests that SLC22A4 is highly specific 
for ergothioneine [9, 10]. Widely expressed in most tis-
sues, SLC22A4 is particularly highly expressed in the 
small intestine where it functions to take ergothioneine 
up from the diet, and in the kidney where it is presumed 
to function in renal reabsorption [5]. A pharmacokinetic 
study of healthy humans taking encapsulated ergothio-
neine (5 and 25 mg/day) found that ergothioneine is rap-
idly absorbed and largely retained by the body, with large 
increases in plasma ergothioneine levels and only mini-
mal increases (< 4%) in urinary excretion observed [11]. 
Avid absorption and retention of ergothioneine has also 
been observed in a study in mice, which showed ergot-
hioneine accumulated in liver as well as whole blood 
[12]. Genetic knockout of SLC22A4 in both mice and 
zebrafish results in almost complete deficiency of ergot-
hioneine in tissues and increased susceptibility to oxida-
tive stress and inflammation, although organisms remain 
viable [8, 13].
The existence of a physiologic transporter for ergot-
hioneine along with its antioxidant and cytoprotective 
roles has raised the question of whether or not ergot-
hioneine should be designated a vitamin [14]. Notably, 
Ames (2018) has proposed that ergothioneine belongs 
to a class of ‘longevity vitamins,’ namely dietary com-
pounds not necessarily required for early survival, but 
that support health and that without which organ-
isms experience accelerated ageing [15]. Supporting 
this idea are data showing that knockout of SLC22A4 
in Caenorhabditis elegans increased oxidative dam-
age and reduced lifespan [16], as well as the afore-
mentioned association of high plasma ergothioneine 
levels with reduced mortality in humans [6]. In a simi-
lar vein, Borodina and colleagues (2020) suggest that 
ergothioneine can be considered a nutraceutical, i.e. a 
nutrient that when taken at higher amounts than typi-
cally found in the diet provides health benefits [4]. 
Indeed, ergothioneine is already sold as a dietary sup-
plement. The European Food Safety Authority (EFSA) 
published their safety assessment and scientific opinion 
for ergothioneine in 2016, determining the no observed 
adverse effect level (NOAEL) of ergothioneine as 800 
mg/kg body weight per day and concluding a supple-
mental dose of 30 mg/day well within safety margins 
[17]. Subsequently, the US Food and Drug Administra-
tion in 2018 approved ergothioneine as generally recog-
nised (GRAS notice 734) [18].
These regulatory approvals facilitate the needed 
intervention trials to investigate the potential health 
benefits of ergothioneine supplementation in humans. 
In spite of the evidence from pre-clinical models and 
studies in humans associating low/high blood levels of 
ergothioneine with disease/health, evidence from ran-
domised controlled trials (RCTs) is lacking. To date, 
only one study, focused on uptake and pharmacoki-
netics, has been published examining ergothioneine 
supplementation in humans [11]. In this placebo-con-
trolled intervention study, 45 participants received 
either placebo, 5 or 25 mg ergothioneine/day for 7 
days and were followed up for an additional 4 weeks; 
there were no reported adverse effects. While no sig-
nificant changes in oxidative or inflammatory markers 
were observed, participants were healthy, the supple-
mentation period was short and the study was likely 
underpowered to examine these. Currently, a larger 
and longer-term study is ongoing in Singapore examin-
ing the efficacy of ergothioneine (25 mg given 3 times a 
week for 52 weeks) to delay or reverse cognitive impair-
ment in elderly individuals with mild cognitive impair-
ment [19]. However, a planned study in the USA that 
aimed to examine the effects of ergothioneine on cogni-
tion, mood and sleep in healthy adults has been termi-
nated in the context of COVID [20].
Metabolic syndrome is a cluster of risk factors asso-
ciated with type 2 diabetes and cardiovascular and 
atherothrombotic diseases [21]. Oxidative stress plays 
an important role in the pathogenesis of metabolic syn-
drome and its downstream morbidities [22]. Given the 
lack of data in humans, in order to address the hypoth-
esis that ergothioneine supplementation may reduce 
markers of systemic and cellular oxidative stress and 
inflammation in people with metabolic syndrome, a 
pilot study is necessary to establish the primary and 
secondary outcomes and power required for a definitive 
RCT. The ErgMS study aims to establish these and will 
be the first study to investigate potential health benefits 
of ergothioneine in people with metabolic syndrome.
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Study aims
The overall aims of this trial are to determine the fea-
sibility of supplementing people with metabolic syn-
drome with ergothioneine for 12 weeks, and to establish 
primary and secondary outcomes and the power 
required for a definitive RCT to establish the benefit of 
ergothioneine on markers of oxidative stress, liver dam-
age, inflammation and metabolic syndrome risk factors 
among people with metabolic syndrome.
Study objectives
1. To assess feasibility of recruiting and supplementing 
people with metabolic syndrome with ergothioneine 
for 12 weeks.
2. To investigate if any changes in serum markers of 
oxidative stress (lipid peroxidation), inflammation 
and liver function can be observed in response to 
ergothioneine supplementation.
3. To examine if any changes in oxidative and inflam-
matory stress in blood immune cells can be observed 
in response to ergothioneine supplementation.
4. To assess if there are any changes in metabolic syn-
drome risk factors or in the serum metabolome in 
response to ergothioneine supplementation.
5. To use the data to determine dose of ergothioneine 
and participant numbers needed to inform a primary 
outcome for a definitive randomised controlled trial.
Study design
The ErgMS study has been designed as a single-centre 
randomised, double-blind, placebo-controlled, 3-arm 
parallel, pilot interventional trial.
Consenting participants with metabolic syndrome 
risk factors will be randomised in a double-blind fash-
ion to one of three parallel arms to receive either pla-
cebo (0 mg ergothioneine), 5 mg ergothioneine or 30 
mg ergothioneine for consumption as daily capsules 
(one per day) for 12 weeks (Fig. 1). The dose of 30 mg 
is well within the NOAEL of 800 mg/kg body weight 
set by EFSA [17]. Participants will give blood samples 
and undergo anthropometric measurements at three 
timepoints, baseline, 6 weeks and 12 weeks (Fig. 1). The 
ErgMS protocol was designed following the Standard 
Protocol Items: Recommendations for Interventional 
Trials (SPIRIT) guidance [23] and has been prospec-
tively registered with the ISCRCTN registry, refer-




The study will be conducted at the School of Food Sci-
ence and Nutrition at the University of Leeds, in Leeds, 
West Yorkshire, the UK.
Eligibility criteria
Inclusion criteria
Consenting participants must be 18–70 years old and 
have risk of metabolic syndrome, defined by presenting 
with at least two of the six following criteria; with cut-
offs based on the 2009 consensus definition of meta-
bolic syndrome and population-specific thresholds for 
defining excess central adiposity [21]:
1. BMI ≥ 25 kg/m2;
2. Abdominal obesity: high waist circumference (Asian/
Asian British—men ≥ 90 cm; women ≥ 80 cm; White 
and all other ethnic groups—men ≥ 94 cm, women 
≥ 80 cm);
3. Fasting glucose ≥ 100 mg/dl (5.6 mmol/l) or treat-
ment for elevated blood glucose;
4. Blood pressure ≥ 130/85 mmHg or treatment for ele-
vated blood pressure;
5. Triacylglycerides (TAG) ≥ 150 mg/dl (1.7 mmol/l) or 
treatment for elevated TAG;
6. Cholesterol-high density lipoprotein (HDL-C) 
< 40 mg/dl (1.0 mmol/l) for male or < 50 mg/dl (1.3 
mmol/l) for female or treatment for low HDL-C.
Exclusion criteria
 1. People who are unwilling or unable to provide 
informed consent;
 2. Women who are pregnant or lactating;
 3. Smokers or people who consume ≥ 28 units of 
alcohol per week (28 units = ~ 10 medium glasses 
of wine (175 ml) or ~ 10 pints of beer/cider);
 4. People following lifestyle change advice, e.g. newly 
implemented diet or exercise regime (≥ 150 min/
week moderate aerobic exercise or ≥ 75 min/week 
vigorous aerobic exercise) aimed at weight loss;
 5. People who have regularly (≥ 3 times/week) taken 
dietary/antioxidant supplements within the last 4 
months;
 6. People taking prescription anti-inflammatory med-
icines (occasional aspirin, paracetamol, ibuprofen 
use acceptable);
 7. Antibiotic treatment within last month or 3 courses 
within the last 6 months;
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Fig. 1 ErgMS Study design. BMI body mass index, BP blood pressure, FFQ food frequency questionnaire, TAG triacylglyceride, HDL-C high-density 
lipoprotein-cholesterol
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 8. Diagnosis of cancer or end of cancer treatment 
within 2 years;
 9. Diagnosis of heart, kidney or gastrointestinal dis-
eases or people who have had surgical treatment 
for obesity;
 10. People diagnosed with a blood borne disease 
(HepB, HIV etc.);
 11. Participation in other clinical trials that may influ-
ence outcomes;
 12. In the context of COVID-19 safe procedures, peo-
ple who cannot wear a face mask during the visit
Consent
Electronic copies of the participant information leaflet 
and consent form will be sent to any potential partici-
pants when they show interest in the ErgMS study and 
provide their email address requesting more information. 
Preliminary screening will be done online and an online 
consent form must be signed before the screening ques-
tionnaire will be released. At the baseline visit, informed 
consent will be confirmed with electronic written con-
sent taken prospectively from the participants by the site 
study team in advance of collecting any data. The consent 
form will ask volunteers to confirm their understanding 
that the samples and data collected will be used to sup-
port other research in the future, and may be shared 
anonymously with other researchers. The form will also 
give potential participants the option to agree to be con-
tacted for future studies. Only adults (> 18 years old) who 
have the capacity to provide consent to participate will 
be included. The ErgMS study will be conducted accord-
ing to the principles of Good Clinical Practice, and to the 
ethical principles that have their origin in the Declaration 
of Helsinki.
Interventions
Consenting participants will be randomised in a double-
blind fashion to one of three intervention groups that 
will receive either placebo (0 mg ergothioneine), 5 mg 
ergothioneine or 30 mg ergothioneine for consumption 
as daily capsules (one per day) for 12 weeks (Fig. 1). Both 
placebo and ergothioneine supplement capsules will be 
manufactured by Tetrahedron (Paris, France). The pla-
cebo capsules will have the same shape, colour, weight 
and packaging as the ergothioneine capsules. Participants 
can withdraw from the study at any time if they want to 
withdraw without reasons by contacting the researcher. 
Data already collected from any withdrawals will be kept 
in the dataset and used in intention-to-treat analysis.
To promote adherence, participants will be sent peri-
odic reminder/enquiry texts before each visit and will 
be informed of their clinical parameters at each visit and 
the final results after the trial data has been analysed and 
unblinded. Supplementation compliance will be measured 
both by capsule counting (participants will be asked to 
return package and untaken supplements at 6 weeks and 12 
weeks) and the measurement of ergothioneine in plasma by 
high-performance liquid chromatography (HPLC) at base-
line, 6 weeks and 12 weeks.
Related to the exclusion criteria, participants will be 
asked not to start taking dietary/antioxidant supplements, 
implement a new diet/fitness regime or take prescription 
anti-inflammatory medicines (occasional aspirin, paraceta-
mol, ibuprofen use acceptable) for the duration of the trial.
Outcomes
Primary feasibility outcomes
1. Recruitment and completion will be measured in the 
numbers of participants enrolling and completing all 
study visits;
2. Supplementation compliance will be measured both 
by capsule counting (participants returning packag-
ing and untaken supplements) and the measurement 
of ergothioneine in plasma by HPLC at baseline, 6 
weeks and 12 weeks.
Secondary exploratory outcomes
At baseline, 6 weeks and 12 weeks, we will measure:
1. A primary serum marker of oxidative stress (specifi-
cally, lipid peroxidation), malondialdehyde (MDA), 
which we hypothesize could be the future primary 
outcome for powering a future definitive trial;
2. Serum markers of inflammation (tumour necrosis 
factor-alpha (TNF-α) protein, nuclear factor eryth-
roid 2-related factor 2 (Nrf2) protein, c-reactive pro-
tein (CRP), soluble CD36, NADPH oxidase 4 (NOX4) 
mRNA) and liver function (ALT);
3. The activation status of blood platelets, platelet reac-
tive oxygen species (ROS) generation and inflamma-
tory platelet-leukocyte aggregates;
4. Metabolic syndrome risk factors: body weight (for 
BMI calculation, height will be measured at baseline 
only) and waist circumference, blood pressure, tria-
cylglyceride (TAG), high-density lipoprotein (HDL) 
cholesterol and fasting glucose;
5. Serum metabolites.
Participant timeline
The participant timeline and schedule of the interven-
tion is outlined in Table  1 in accordance with SPIRIT 
guidelines.
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Sample size
As a consequence of a complete lack of data on which to 
base either a primary outcome or a formal power calcula-
tion, and in line with the appropriate CONSORT exten-
sion [24], a primary aim of this pilot trial is to generate 
the data to inform the design of a definitive trial. The 
decision to recruit a total 108 participants was a prag-
matic one based both on statistical arguments for sample 
size in pilot/feasibly trials and the need to balance maxi-
mizing precision while minimizing the impacts of size 
Table 1 Participant timeline from initial screening to end of study
a t1, baseline; t2, 6 weeks, t3 12 weeks
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on resources, time and costs [25, 26]. With a goal of 90 
measured participants (30 per group), we aim to recruit 
108 participants to allow for 20% drop out per group. 
This number is in line with previous calculations suggest-
ing between 25 and 35 participants per group will typi-
cally provide sufficient power to determine the effect size 
for a sample size calculation without being wasteful of 
resources [25–27].
Recruitment
We will recruit participants in several ways. People 
with metabolic syndrome who participated in a previ-
ous study in our School (the PATHWAY-27 study [28]), 
and consented to be contacted again for other research 
studies, will be contacted by phone or email to ask if 
they are interested in taking part in another intervention 
trial. We will also advertise the study broadly through 
conventional and social media and via multiple relevant 
charities (e.g. British Heart Foundation and Diabe-
tes UK). We aim to achieve Health Research Authority 
approval, which will also permit recruitment through 
general practitioners’ offices. Based on experience with 
the PATHWAY-27 study [28], we anticipate recruitment 
and running of the trial to take 2 years. In the context of 
unforeseen risk events such as COVID19 or low recruit-




While enrolment will be done by the study team, the ran-
domisation schedule and allocation will be carried out by 
a collaborator who will not be involved in any other part 
of this trial and who will also be blinded to the dose allo-
cation (Interventions ‘1’, ‘2’ or ‘3’; Fig. 1) designated by the 
manufacturer and provided in a sealed envelope. Ran-
domisation and group allocation will be done based on 
predefined random allocation lists using simple stratifica-
tion for sex (one each for males and females), with a block 
size of 6 and allocation list of 2:2:2; aiming to recruit 108 
participants for n = 36 in each group.
Blinding
Both participants and researchers, including research 
team members and the collaborator, will be blinded to 
the dose allocation. The collaborator will maintain the 
dose allocation lists matching screening IDs to ran-
domisation IDs, along with the manufacturer’s sealed 
envelope for the duration of the trial. This envelope will 
only be opened before study completion in the case of 
a serious adverse event. To test the success of blinding, 
2 external questions will be added in the final visit of 
the health questionnaire—‘What dose of ergothioneine 
did you think you were taking during this period?’ & 
‘Why?’.
Data collection, management and analysis
Data collection methods
Participants will give fasted blood samples and undergo 
anthropometric measurements at three timepoints, 
baseline, 6 weeks and 12 weeks. All the clinical data 
(metabolic syndrome risk factors) will be recorded 
in clinical research files. As detailed in the data man-
agement plan below, these will be scanned and cop-
ies saved electronically as well as in physical format. At 
each visit, participants will be asked to complete a brief 
online health questionnaire and an online food fre-
quency questionnaire (FFQ) adapted from our validated 
short (45-item) FFQ [29] to include food items rich in 
ergothioneine.
Blood sample collection
Minimal amounts of blood will be taken from par-
ticipants to limit the burden of bleeding. At three 
timepoints: baseline (before starting capsule supple-
mentation), 6 weeks follow-up and end of the study, we 
will ask to take a finger prick blood sample to measure 
participants blood TAG, HDL cholesterol, fasting glu-
cose and CRP. In addition, participants will be asked to 
provide 15 ml of blood sample for measurement of plate-
let function, inflammatory biomarkers and metabolites. 
Fifteen milliliters of blood donation is safe for adults and 
venepuncture will be done by a trained phlebotomist to 
ensure that distress during blood collection will be mini-
mal and that correct procedures for collection, process-
ing and storage are followed. Five milliliters of whole 
blood will be immediately used for platelet function 
assays using multicolour flow cytometry assessment of 
surface markers of platelet activation, platelets subsets, 
platelet ROS generation and platelet-leukocyte aggre-
gates [30]. Platelet function will be addressed under 
basal conditions in order to evaluate activation status of 
circulating platelets and after stimulation with known 
agonists to examine if their propensity for activation is 
altered. The remaining 10 ml will be centrifuged for the 
collection of acellular serum, aliquoted and stored at 
− 80 °C for future laboratory analysis. Stored serum will 
be compliant (i.e. exempt from regulation) with the 2004 
Human Tissue Act.
Metabolic syndrome risk factors
Height will be measured with a stadiometer at baseline. 
Bodyweight, blood pressure, waist circumference will be 
measured with a beam scale, blood pressure monitor and 
tape respectively at baseline, 6 weeks and 12 weeks. TAG, 
HDL-C and fasting glucose will be measured in whole 
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blood using a rapid point-of-care multi-assay blood 
analyser (Afinion 2 analyser; Abbott, UK) at baseline, 6 
weeks and 12 weeks.
Biomarkers assessment
CRP will also be measured from a finger prick of whole 
blood by a rapid point-of-care multi-assay blood analyser. 
MDA will be measured in purified serum samples by 
HPLC. The TNF-α and Nrf2 proteins will be measured in 
purified serum samples using  enzyme-linked immuno-
sorbent assay (ELISA) kits.  NOX4 mRNA expression will 
be measured in purified serum samples by quantitative 
polymerase chain reaction. ALT activity will be measured 
in serum samples using a commercial assay kit.
Metabolite assessment
 Ergothioneine and its metabolites (hercynine, ergothio-
neine sulfonate and S-methyl ergothioneine), as well as 
other metabolites will be measured in serum by liquid 
chromatography-mass spectrometry (LC-MS).
Online questionnaires
Online health questionnaire and FFQs will be used to 
record the health condition, dietary habit and quality at 
baseline (visit 1), 6 weeks (visit 2) and end of the study 
(12 weeks, visit 3).
Data management, confidentiality and access
All data will be managed through a Microsoft Access 
database with data entered using encrypted, two-factor 
authentication protected, computers owned by the Uni-
versity of Leeds. Electronic data will be stored on the 
University of Leeds SAN (Storage Area Network), which 
comprises enterprise level disk storage and file servers 
located in physically secure data centres with appropriate 
fire suppression equipment and daily/monthly/long-term 
back up protocols. The SAN is located behind the Uni-
versity’s Institutional firewall to protect against external 
attacks.
Physical format clinical research files (used to collect 
clinical data during visits; template available in appen-
dix  of our  approved ethics application) will be scanned 
and copies saved electronically as well as in physical for-
mat in locked cabinet in the chief investigator’s secure 
office. Data entry from clinical research files will be 
confirmed independently by second investigator. Ques-
tionnaires (primary eligibility screening questionnaire, 
health questionnaires, FFQs) will be collected in a digital 
format.
Data will be collected anonymised with only partici-
pants’ randomisation number and date of birth recorded 
on the data collection tools. Anonymised data will be 
shared, published and used in line with the University 
of Leeds Research Data Management Policy. Any per-
sonal details, identifiable or sensitive information will 
not appear in any publications. The data will be retained 
for at least 2 years after publication. Only research team 
members will have access to the data.
Statistical methods
Descriptive statistics will be used initially to present 
the basic features of the data, with data presented as 
mean/SD or percentage used as appropriate in response 
to normality testing using (Table  2). Linear regres-
sion and two-way ANOVA will be performed to ana-
lyse the associations between variables (Table  3). The 
significance level will be set at 5% and 95% confidence 
intervals will be presented. Intention-to-treat analysis 
will be performed to compare the difference with per-
protocol analysis. Basic analyses will be performed in 
GraphPad Prism. Multivariate linear regression will be 
done either in STATA or the R environment in con-
sultation with statistician/mathematical modeller as 
required.
Monitoring
The ErgMS trial management group will be comprised 
of the Chief (JBM) and lead investigators (XT, JS, JT) 
and will be responsible for the day-to-day running 
and management of the trial. As ergothioneine is an 
amino acid normally found in food and the doses of 
ergothioneine being tested (5 or 30 mg/day) are well 
below the safety limit (800 mg/kg bodyweight per 
day—e.g. a total of 56,000 mg/day for a 70 kg adult), 
the risk of harm or adverse event for adult participants 
with metabolic syndrome is considered low. Ergothio-
neine has minimal allergy risk determined by Euro-
pean Food Safety Authority [17]. Participants will be 
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asked to inform the researcher if they feel unwell at 
any point during the study and their general health will 
be assessed through the health questionnaire at the 6- 
and 12-week visits.
Any participant reported adverse events will be 
recorded by the member of the trial management group 
in our adverse event reporting form and immediately 
report it to the Chief Investigator and assessed for cau-
sality. As necessary, the participant will be advised to 
consult their GP or relevant healthcare professional. 
In light of the relatively low risk study population with 
a noncritical indication (adults with metabolic syn-
drome), use of a food supplement with minimal risk, 
and short study duration, the ErgMS study does not 
have an independent data monitoring committee. In 
the unlikely event of a serious adverse event (SAE), the 
participant’s allocated intervention will be unblinded 
and the SAE and allocation will be reported to the 
Research Ethics Committee and the supplement manu-
facturer. Although there are minimal risks anticipated 
for this study, any adverse event or serious adverse 
event will be described according to its relatedness 
with the interventions, for both the total sample and by 
intervention arms, in the final study report.
Protocol amendments
Any modifications of the protocol that may affect the 
conduct of the study, participant recruitment, the infor-
mation provided to participants or the data analysis will 
be submitted to the University of Leeds Research Eth-
ics Committee as an amendment and communicated to 
ISRCTN after approval. As necessary, any changes affect-
ing participants currently enrolled will be communicated 
to participants after approval and being applied to the 
study.
Dissemination plans
Regardless of the magnitude or direction of effect, the 
results will be disseminated in a timely fashion through 
presentation first at scientific conferences and then via 
publication in open access, peer-reviewed journals. In 
addition, progress reports and results will be available 
on the trial website and communicated via social media 
to a wider audience. The full protocol, and ultimately the 
anonymised dataset and any relevant statistical code, will 
be deposited in the Leeds Research Data Repository and 
available open access.
Discussion
Ergothioneine is a dietary nutrient that is sold as a die-
tary supplement for its antioxidant and anti-inflamma-
tory properties. However, to date, there are no published 
intervention trials examining its efficacy in humans. 
Therefore, along with examining feasibility, the ErgMS 
study aims to establish primary and secondary outcomes, 
and the power required, for a definitive randomised con-
trolled trial to test the hypothesis that ergothioneine 
supplementation is beneficial for people with metabolic 
syndrome.
A significant body of preclinical data has demon-
strated antioxidant and anti-inflammatory activities of 
ergothioneine that are relevant to the prevention of car-
diometabolic diseases [4, 5]. These data underpinned 
our decision to first investigate ergothioneine in people 
with metabolic syndrome, who are at risk of developing 
diabetes and non-alcoholic fatty liver disease (NAFLD), 
as well as cardiovascular and atherothrombotic diseases 
[21]. Considered the hepatic manifestation of the meta-
bolic syndrome [31], NAFLD involves chronic oxidative 
metabolism, lipid peroxidation and inflammation that 
can progress to liver fibrosis [32]. Interestingly, ergot-
hioneine has been shown to be protective in both animal 
models of NAFLD [33] and liver fibrosis [34], informing 
our measurement of MDA, a primary serum marker of 
Table 3 ErgMS measurements and schedule
ALT Alanine transaminase, BMI Body mass index, BP Blood pressure, CRP 
C-reactive protein, HDL-C High-density lipoprotein-cholesterol, MDA 
Malondialdehyde, Nrf2 Nuclear factor erythroid 2-related factor 2, TAG 
Triacylglyceride, TNF-α Tumour necrosis factor-alpha, WC Waist circumference, 
wks Weeks
Measurement Study visit
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lipid peroxidation, as well as ALT, a marker of liver func-
tion in this study. Similarly, several of the inflammatory 
markers we intend to measure have been shown to be 
modulated in protective fashion by ergothioneine in pre-
clinical models; e.g. TNF-α [35], Nrf2 [36] and NOX4 
[34]. In the context of COVID-19, a possible factor affect-
ing measures of inflammation might be vaccination 
timing, and this information will be collected from par-
ticipants and examined as a potential confounder.
Alterations in platelet function, including platelet 
hyperaggregability and hyperactivation is commonly 
seen in people with metabolic syndrome and contributes 
fundamentally to the increased risk of atherothrombotic 
diseases [37, 38]. Oxidative stress plays a critical role in 
platelet hyperactivity, with platelet activation driven by 
ROS present both in the vasculature and generated by 
platelets themselves. Dietary antioxidant intakes are 
inversely associated with cardiovascular and athero-
thrombotic diseases [39], and multiple dietary supple-
ments and nutraceuticals have been shown to impact 
platelet function [40–42]. Although the antioxidant activ-
ities of ergothioneine in scavenging hydroxyls and other 
free radicals is well documented [3], to date the role of 
ergothioneine in human platelet function has not been 
explored. Therefore in the ErgMS study, we will assess 
platelet function using multicolour flow cytometry to 
measure surface markers of platelet activation, platelets 
subsets, platelet ROS generation and platelet-leukocyte 
aggregates [30].
Potential limitations to this study exist, including the 
fact that there were no data on which to base the length 
of supplementation period for ergothioneine. There-
fore, the decision to supplement for 12 weeks, with 
measurements also taken at 6 weeks was a pragmatic 
one. Although serum MDA has been shown to respond 
to intervention with other dietary supplements within 
12 weeks [43, 44], these are not directly comparable to 
ergothioneine. Likewise, there were no data on which to 
base the dose of ergothioneine for supplementing people 
with metabolic syndrome, and pragmatically the decision 
was based to supplement with the amounts (5 mg and 30 
mg) commonly available and well within the safety mar-
gins defined by EFSA [17]. In the only human study pub-
lished to date, where healthy participants received either 
placebo, 5 or 25 mg ergothioneine/day for 7 days, a dose-
dependent effect on levels of ergothioneine in plasma, 
urine and whole blood were observed [11]. However, 
data from mice orally administered either saline, 35 or 
70 mg/kg ergothioneine per day for 1, 7 or 28 days, sug-
gests saturation kinetics exist for ergothioneine uptake 
and accumulation in animal tissues [12]. Therefore, it is 
difficult to predict whether the lower or higher dose of 
ergothioneine may be more beneficial over 12 weeks for 
people with metabolic syndrome.
An additional potential implication from the ErgMS 
design is that while the exclusion criteria reflect our 
objective of focusing on metabolic syndrome and 
excluding other inflammatory conditions, the large 
number of exclusion criteria may result in a longer 
recruitment period. Nonetheless, the ErgMS study will 
be the first study to address the question does ergothio-
neine supplementation have health benefits for people 
with metabolic syndrome. Study results will provide 
novel, preliminary data as to which dose may improve 
inflammatory markers in adults with metabolic syn-
drome, and inform dose and primary outcome selec-
tion for a definitive RCT.
Abbreviations
ALT: Alanine transaminase; CRP: C-reactive protein; EFSA: European Food 
Safety Authority; ELISA: Enzyme-linked immunosorbent assay; FFQ: Food 
Frequency Questionnaire; HDL: High-density lipoprotein; HPLC: High-
performance liquid chromatography; LC-MS: Liquid chromatography-mass 
spectrometry; MDA: Malondialdehyde; NOX4: NADPH oxidase 4; Nrf2: Nuclear 
factor erythroid 2-related factor 2; RCT : Randomised controlled trial; ROS: 
Reactive oxygen species; SLC22A4: Solute carrier family 22 member 4; TAG : 
Triacylglyceride; TNF-α: Tumour necrosis factor-alpha.
Supplementary Information
The online version contains supplementary material available at https:// doi. 





XT, JLT and JBM designed the ErgMS study protocol; XT and JBM drafted the 
manuscript. GC, JHS, KMN and JLT edited the manuscript. All authors approved 
the final version.
Funding
The ErgMS study is funded by the School of Food Science and Nutrition, 
University of Leeds and Tetrahedron (Paris, France) who will manufacture, pack 
and provide both the placebo and ergothioneine capsules. Tetrahedron has 
had no role in the study design, will have no role in the conduct of this study 
and will not influence data collection, data management, data analysis and 
dissemination.
Availability of data and materials
Not applicable.
Declarations
Ethics approval and consent to participate
Ethical approval for the ErgMS Study was granted 11/12/2020 by the Engi-
neering and Physical Sciences Faculty Research Ethics Committee (University 
of Leeds, LS2 9NL; EPSRe searc hEthi cs@ leeds. ac. uk), reference: MEEC 20-007 
(current protocol version 4.0 17/08/21). Additionally, the platelet experi-
ments with human samples has also been approved by the Leeds School of 
Medicine Research Ethics Committee (University of Leeds, LS2 9NL; FMHUn 
iEthi cs@ leeds. ac. uk), reference M19-007. This trial was prospectively registered 
Page 11 of 12Tian et al. Pilot Feasibility Stud           (2021) 7:193  





The authors declare no competing interests.
Author details
1 School of Food Science & Nutrition, University of Leeds, Leeds LS2 9JT, UK. 
2 Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, 
Leeds LS2 9JT, UK. 
Received: 28 April 2021   Accepted: 12 October 2021
References
 1. Ey J, Schomig E, Taubert D. Dietary sources and antioxidant effects of 
ergothioneine. J Agric Food Chem. 2007;55(16):6466–74.
 2. Halliwell B, Cheah IK, Tang RMY. Ergothioneine—a diet-derived antioxi-
dant with therapeutic potential. FEBS Lett. 2018;592(20):3357–66.
 3. Cheah IK, Halliwell B. Ergothioneine; antioxidant potential, 
physiological function and role in disease. Biochim Biophys Acta. 
2012;1822(5):784–93.
 4. Borodina I, Kenny LC, McCarthy CM, Paramasivan K, Pretorius E, Roberts 
TJ, et al. The biology of ergothioneine, an antioxidant nutraceutical. 
Nutr Res Rev. 2020;33(2):190–217.
 5. Cheah IK, Halliwell B. Ergothioneine, recent developments. Redox Biol. 
2021:101868. https:// doi. org/ 10. 1016/j. redox. 2021. 101868.
 6. Smith E, Ottosson F, Hellstrand S, Ericson U, Orho-Melander M, Fernan-
dez C, et al. Ergothioneine is associated with reduced mortality and 
decreased risk of cardiovascular disease. Heart. 2020;106(9):691–7.
 7. Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, et al. 
Discovery of the ergothioneine transporter. Proc Natl Acad Sci U S A. 
2005;102(14):5256–61.
 8. Kato Y, Kubo Y, Iwata D, Kato S, Sudo T, Sugiura T, et al. Gene knockout 
and metabolome analysis of carnitine/organic cation transporter 
OCTN1. Pharm Res. 2010;27(5):832–40.
 9. Tschirka J, Kreisor M, Betz J, Grundemann D. Substrate selectiv-
ity check of the ergothioneine transporter. Drug Metab Dispos. 
2018;46(6):779–85.
 10. Yee SW, Buitrago D, Stecula A, Ngo HX, Chien HC, Zou L, et al. 
Deorphaning a solute carrier 22 family member, SLC22A15, through 
functional genomic studies. Faseb J. 2020;34(12):15734–52.
 11. Cheah IK, Tang RM, Yew TS, Lim KH, Halliwell B. Administration of pure 
ergothioneine to healthy human subjects: uptake, metabolism, and 
effects on biomarkers of oxidative damage and inflammation. Antioxid 
Redox Signal. 2017;26(5):193–206.
 12. Tang RMY, Cheah IK, Yew TSK, Halliwell B. Distribution and accumula-
tion of dietary ergothioneine and its metabolites in mouse tissues. Sci 
Rep. 2018;8(1):1601.
 13. Pfeiffer C, Bach M, Bauer T, Campos da Ponte J, Schomig E, Grunde-
mann D. Knockout of the ergothioneine transporter ETT in zebrafish 
results in increased 8-oxoguanine levels. Free Radic Biol Med. 
2015;83:178–85.
 14. Paul BD, Snyder SH. The unusual amino acid L-ergothioneine is a physi-
ologic cytoprotectant. Cell Death Differ. 2010;17(7):1134–40.
 15. Ames BN. Prolonging healthy aging: longevity vitamins and proteins. 
Proc Natl Acad Sci U S A. 2018;115(43):10836–44.
 16. Cheah IK, Ong RL, Gruber J, Yew TS, Ng LF, Chen CB, et al. Knockout 
of a putative ergothioneine transporter in Caenorhabditis elegans 
decreases lifespan and increases susceptibility to oxidative damage. 
Free Radic Res. 2013;47(12):1036–45.
 17. EFSA Panel on Dietetic Products N, Allergies, Turck D, Bresson J-L, 
Burlingame B, Dean T, et al. Safety of synthetic l-ergothioneine 
(Ergoneine®) as a novel food pursuant to Regulation (EC) No 258/97. 
EFSA J. 2016;14(11):e04629.
 18. USFDA. Re: GRAS Notice No. GRN 000734. 2018. Available from: https:// 
www. fda. gov/ media/ 113846/ downl oad.
 19. Cheah IK, Mahendran R, Halliwell B. Investigating the efficacy of ergot-
hioneine to delay cognitive decline: ClinicalTrial.gov; 2018. Available 
from: https:// clini caltr ials. gov/ ct2/ show/ NCT03 641404.
 20. Midwest Center for Metabolic and Cardiovascular Research. Effects of 
ergothioneine on cognition, mood, and sleep in healthy adult men 
and women: ClinicalTrial.gov; 2020. Available from: https:// clini caltr ials. 
gov/ ct2/ show/ NCT04 556032.
 21. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, 
et al. Harmonizing the metabolic syndrome: a joint interim statement of 
the International Diabetes Federation Task Force on Epidemiology and 
Prevention; National Heart, Lung, and Blood Institute; American Heart 
Association; World Heart Federation; International Atherosclerosis Soci-
ety; and International Association for the Study of Obesity. Circulation. 
2009;120(16):1640–5.
 22. Mahjoub S, Masrour-Roudsari J. Role of oxidative stress in pathogenesis 
of metabolic syndrome. Caspian J Intern Med. 2012;3(1):386–96.
 23. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić 
K, et al. SPIRIT 2013 statement: defining standard protocol items for 
clinical trials. Ann Intern Med. 2013;158(3):200–7.
 24. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane 
L, et al. CONSORT 2010 statement: extension to randomised pilot and 
feasibility trials. Pilot Feasibility Stud. 2016;2:64.
 25. Stallard N. Optimal sample sizes for phase II clinical trials and pilot 
studies. Stat Med. 2012;31(11-12):1031–42.
 26. Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters 
SJ. Sample size requirements to estimate key design parameters from 
external pilot randomised controlled trials: a simulation study. Trials. 
2014;15(1):264.
 27. Schoenfeld D. Statistical considerations for pilot studies. Int J Radiat 
Oncol Biol Phys. 1980;6(3):371–4.
 28. Bub A, Malpuech-Brugère C, Orfila C, Amat J, Arianna A, Blot A, et al. A 
dietary intervention of bioactive enriched foods aimed at adults at risk 
of metabolic syndrome: protocol and results from PATHWAY-27 pilot 
study. Nutrients. 2019;11(8):1814.
 29. Bredin C, Naimimohasses S, Norris S, Wright C, Hancock N, Hart K, 
et al. Development and relative validation of a short food frequency 
questionnaire for assessing dietary intakes of non-alcoholic fatty liver 
disease patients. Eur J Nutr. 2020;59(2):571–80.
 30. Hindle MS, Spurgeon BEJ, Cheah LT, Webb BA, Naseem KM. Multidi-
mensional flow cytometry reveals novel platelet subpopulations in 
response to prostacyclin. J Thromb Haemost. 2021;19(7):1800–12.
 31. Moore JB. Non-alcoholic fatty liver disease: the hepatic conse-
quence of obesity and the metabolic syndrome. Proc Nutr Soc. 
2010;69(2):211–20.
 32. Moore JB. From sugar to liver fat and public health: systems biology 
driven studies in understanding non-alcoholic fatty liver disease 
pathogenesis. Proc Nutr Soc. 2019;78(3):290–304.
 33. Cheah IK, Tang R, Ye P, Yew TS, Lim KH, Halliwell B. Liver ergothio-
neine accumulation in a guinea pig model of non-alcoholic fatty 
liver disease. A possible mechanism of defence? Free Radic Res. 
2016;50(1):14–25.
 34. Tang Y, Masuo Y, Sakai Y, Wakayama T, Sugiura T, Harada R, et al. 
Localization of xenobiotic transporter OCTN1/SLC22A4 in hepatic 
stellate cells and its protective role in liver fibrosis. J Pharm Sci. 
2016;105(5):1779–89.
 35. Salama SA, Omar HA. Modulating NF-κB, MAPK, and PI3K/AKT signaling 
by ergothioneine attenuates iron overload-induced hepatocellular 
injury in rats. J Biochem Mol Toxicol. 2021;35(5):e22729.
 36. Dare A, Elrashedy AA, Channa ML, Nadar A. Cardioprotective effects 
and in-silico antioxidant mechanism of L-ergothioneine in experimen-
tal type-2 diabetic rats. Cardiovasc Hematol Agents Med Chem. 2021. 
https:// doi. org/ 10. 2174/ 18715 25719 66621 08091 22541.
 37. Wang T, Xu J, Fu L, Li L. Hypertriglyceridemia is associated with platelet 
hyperactivation in metabolic syndrome patients. Int J Clin Pract. 
2020;74(7):e13508.
Page 12 of 12Tian et al. Pilot Feasibility Stud           (2021) 7:193 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 38. Barale C, Russo I. Influence of cardiometabolic risk factors on platelet 
function. Int J Mol Sci. 2020;21(2):623.
 39. Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, 
et al. Dietary intake and blood concentrations of antioxidants and the 
risk of cardiovascular disease, total cancer, and all-cause mortality: a 
systematic review and dose-response meta-analysis of prospective 
studies. Am J Clin Nutr. 2018;108(5):1069–91.
 40. Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc 
Biol. 2008;28(3):s11–6.
 41. Wang CZ, Moss J, Yuan CS. Commonly used dietary supple-
ments on coagulation function during surgery. Medicines (Basel). 
2015;2(3):157–85.
 42. Olas B. Dietary supplements with antiplatelet activity: a solution for 
everyone? Adv Nutr. 2018;9(1):51–7.
 43. Henning T, Weber D. Redox biomarkers in dietary interventions and 
nutritional observation studies - From new insights to old problems. 
Redox Biol. 2021;41:101922.
 44. Asbaghi O, Ghanavati M, Ashtary-Larky D, Bagheri R, Rezaei Kelishadi M, 
Nazarian B, et al. Effects of folic acid supplementation on oxidative stress 
markers: a systematic review and meta-analysis of randomized controlled 
trials. Antioxidants (Basel). 2021;10(6):871.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
